Nakahara Satoshi, Ishii Yumiko, Egashira Reika, Tsubouchi Kazuya, Kohno Mikihiro, Takenaka Tomoyoshi, Tanaka Kentaro, Okamoto Isamu
Department of Respiratory Medicine, Graduate School of Medical Sciences Kyushu University Fukuoka Japan.
Department of Surgery and Science, Graduate School of Medical Sciences Kyushu University Fukuoka Japan.
Respirol Case Rep. 2024 Apr 25;12(5):e01334. doi: 10.1002/rcr2.1334. eCollection 2024 May.
We report the first case of drug-induced interstitial lung disease attributed to lemborexant. A 66-year-old man reported to our hospital with the acute onset of cough and breathlessness with ground-glass opacity on radiological examination. Symptoms were identified after taking lemborexant for 2 consecutive days. The patient had undergone lemborexant treatment 2 years prior and had exhibited no symptoms at that time. The drug-induced lymphocyte stimulation test for lemborexant was positive. He showed rapid improvement upon treatment with steroid. With the rise in prescriptions of lemborexant for insomnia, lemborexant should be considered as a possible cause of drug-induced interstitial lung disease.
我们报告了首例由伦博瑞生引起的药物性间质性肺病病例。一名66岁男性因咳嗽和呼吸困难急性发作前来我院就诊,影像学检查显示磨玻璃影。症状是在连续服用伦博瑞生2天后出现的。该患者2年前曾接受过伦博瑞生治疗,当时未出现症状。伦博瑞生的药物诱导淋巴细胞刺激试验呈阳性。经类固醇治疗后,他的症状迅速改善。随着用于失眠的伦博瑞生处方量的增加,应考虑伦博瑞生可能是药物性间质性肺病的病因。